These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 27541499)

  • 1. Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism.
    Arachchillage DR; Mackie IJ; Efthymiou M; Chitolie A; Hunt BJ; Isenberg DA; Khamashta M; Machin SJ; Cohen H
    J Thromb Haemost; 2016 Nov; 14(11):2177-2186. PubMed ID: 27541499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.
    Cohen H; Doré CJ; Clawson S; Hunt BJ; Isenberg D; Khamashta M; Muirhead N;
    Lupus; 2015 Sep; 24(10):1087-94. PubMed ID: 25940537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome: Rationale and design of the Trial on Rivaroxaban in AntiPhospholipid Syndrome (TRAPS) trial.
    Pengo V; Banzato A; Bison E; Zoppellaro G; Padayattil Jose S; Denas G
    Lupus; 2016 Mar; 25(3):301-6. PubMed ID: 26466613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in patients with nontriple antiphospholipid syndrome (APS) anticoagulated with rivaroxaban.
    Htut TW; Milne D; Khan MM; Watson HG
    Int J Lab Hematol; 2021 Oct; 43(5):e252-e253. PubMed ID: 33470532
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebral Venous Thromboembolism in Antiphospholipid Syndrome Successfully Treated with the Combined Use of an Anti-Xa Inhibitor and Corticosteroid.
    Sugie M; Iizuka N; Shimizu Y; Ichikawa H
    Intern Med; 2015; 54(23):3051-6. PubMed ID: 26631891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial.
    Cohen H; Hunt BJ; Efthymiou M; Arachchillage DR; Mackie IJ; Clawson S; Sylvestre Y; Machin SJ; Bertolaccini ML; Ruiz-Castellano M; Muirhead N; Doré CJ; Khamashta M; Isenberg DA;
    Lancet Haematol; 2016 Sep; 3(9):e426-36. PubMed ID: 27570089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
    Pengo V; Denas G; Zoppellaro G; Jose SP; Hoxha A; Ruffatti A; Andreoli L; Tincani A; Cenci C; Prisco D; Fierro T; Gresele P; Cafolla A; De Micheli V; Ghirarduzzi A; Tosetto A; Falanga A; Martinelli I; Testa S; Barcellona D; Gerosa M; Banzato A
    Blood; 2018 Sep; 132(13):1365-1371. PubMed ID: 30002145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome.
    Arachchillage DR; Mackie IJ; Efthymiou M; Isenberg DA; Machin SJ; Cohen H
    J Thromb Haemost; 2015 Jul; 13(7):1264-73. PubMed ID: 25850997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    Thromb Res; 2015 Feb; 135(2):388-93. PubMed ID: 25555316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apixaban Versus Vitamin K Antagonists in Patients With Antiphospholipid Syndrome: A Cohort Study.
    Sikorska M; Chmiel J; Papuga-Szela E; Broniatowska E; Undas A
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):36-44. PubMed ID: 38922590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent venous thromboembolism after discontinuation of rivaroxaban therapy in a patient with antiphospholipid syndrome.
    Yagi S; Nishiyama S; Abe T; Sata M
    BMJ Case Rep; 2019 Jan; 12(1):. PubMed ID: 30635311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome: A Randomized Noninferiority Trial.
    Ordi-Ros J; Sáez-Comet L; Pérez-Conesa M; Vidal X; Riera-Mestre A; Castro-Salomó A; Cuquet-Pedragosa J; Ortiz-Santamaria V; Mauri-Plana M; Solé C; Cortés-Hernández J
    Ann Intern Med; 2019 Nov; 171(10):685-694. PubMed ID: 31610549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome.
    Efthymiou M; Lawrie AS; Mackie I; Arachchillage D; Lane PJ; Machin S; Cohen H
    Thromb Res; 2015 Jun; 135(6):1191-7. PubMed ID: 25895847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. After failure with acenocoumarol, rivaroxaban in antiphospholipid syndrome: A report of 2 cases.
    Mateos Rodríguez JJ; Bellido D; Castro D; Portillo Sánchez J; Vanegas R; Núñez García A
    Reumatol Clin (Engl Ed); 2019; 15(5):e33-e35. PubMed ID: 28546102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivaroxaban Versus Warfarin and Risk of Post-Thrombotic Syndrome Among Patients with Venous Thromboembolism.
    Søgaard M; Nielsen PB; Skjøth F; Kjældgaard JN; Coleman CI; Larsen TB
    Am J Med; 2018 Jul; 131(7):787-794.e4. PubMed ID: 29476744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome.
    Arachchillage DR; Efthymiou M; Mackie IJ; Lawrie AS; Machin SJ; Cohen H
    J Thromb Haemost; 2014 Nov; 12(11):1801-9. PubMed ID: 25196808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study.
    Hendriks T; McGregor S; Rakesh S; Robinson J; Ho KM; Baker R
    PLoS One; 2020; 15(6):e0234048. PubMed ID: 32497116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of direct oral anticoagulants in antiphospholipid syndrome.
    Cohen H; Efthymiou M; Isenberg DA
    J Thromb Haemost; 2018 Jun; 16(6):1028-1039. PubMed ID: 29624847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.